Delving into the Latest Updates on CLR-200 series (Clera) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

dopamine D2 partial agonist/D1 agonist (Clera)

Target

D1 receptor x D2 receptor

Action

agonists, partial agonists

Mechanism

D1 receptor agonists(Dopamine D1 receptor agonists), D2 receptor partial agonists(Dopamine D2 receptor partial agonists)

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Depressive Disorder

Originator Organization

Clera Inc.

Active Organization-

Inactive Organization

Clera Inc.

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

L-Stepholidine (l-SPD), an alkaloid extract of the Chinese herb Stephania intermedia, is the first compound known to exhibit mixed dopamine D1 receptor agonist/D2 antagonist properties and is a potential medication for the treatment of opiate addiction. The aim of the present study was to investigate the effects of pretreatment with L-SPD on heroin-seeking behavior induced by heroin priming. Male Sprague-Dawley rats were trained to self-administer heroin (0.05mg/kg per infusion) under a fixed ratio 1 schedule for 12 consecutive days and nose-poke responding was extinguished for 12 days, after which reinstatement of drug seeking was induced by heroin priming. Pretreatment with L-SPD (2.5, 5.0 and 10.0mg/kg, i.p.) inhibited the heroin-induced reinstatement of heroin-seeking behavior. Importantly, L-SPD did not affect locomotion, indicating that the observed effects of L-SPD on reinstatement are not the result of motor impairments. The present data suggested that l-SPD inhibits heroin-induced reinstatement and its potential for the treatment of heroin relapse.

100 Deals associated with CLR-200 series (Clera)

Login to view more data